Real-life effectiveness of dupilumab in patients with mild to moderate bronchial asthma comorbid with CRSwNP

BACKGROUND: Dupilumab, an anti-IL-4α receptor antibody, is a new treatment for severe or refractory asthma. However, real-world evidence on the efficacy of dupilumab in patients with mild to moderate bronchial asthma is lacking. METHODS: We retrospectively evaluated the effects of dupilumab in 62 pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Minagawa, Shunsuke, Araya, Jun, Watanabe, Naoaki, Fujimoto, Shota, Watanabe, Junko, Hara, Hiromichi, Numata, Takanori, Kuwano, Kazuyoshi, Matsuwaki, Yoshinori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9241284/
https://www.ncbi.nlm.nih.gov/pubmed/35764984
http://dx.doi.org/10.1186/s12890-022-02046-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9241284/
https://www.ncbi.nlm.nih.gov/pubmed/35764984
http://dx.doi.org/10.1186/s12890-022-02046-3

Ejemplares similares